четверг, 6 октября 2011 г.

Cervical Cancer Vaccine Could Save Nearly 193,333 Lives A Year

It is estimated that 290,000 women die of cervical cancer globally each year. If Gardasil could reduce deaths by two-thirds, as Merck claims, this would mean 193,333 women's lives saved each year. In order to be effective, Merck says it would be best to vaccinate girls before they are likely to become sexually active.


Gardasil, a vaccine, prevents infection of four types of HPV (human papillomavirus). Two of them, types 16 and 18, are responsible for the development of over two-thirds of all cervical cancers. The other two types are responsible for most genital warts.


Merck says this could be the biggest cervical cancer prevention leap since the PAP test.


Today, an FDA Adisory Panel must decide whether or not to recommend Gardasil for approval. The Panel does not approve new drugs, it just recommends whether or not they should be approved. The FDA itself approves or declines drug applications. However, the FDA usually does what the Panel recommends. A decision on Gardasil is expected on 8 June.


HPV is a sexually transmitted infection (STI) and is present in about half of all sexually active adults.


If people who are already HPV infected take the vaccine and their immune systems have not cleared the virus from their systems, their risk of having a cancer precursor is higher. Five women who had the vaccine at about the same time as they became pregnant (conception) went on to have babies with birth defects.


The vaccine will not be cheap. A course of three injections over a six month period will cost from $300 to $500.







View drug information on Gardasil.



четверг, 29 сентября 2011 г.

Agile Therapeutics Presents Additional Data At ACOG Meeting On Lead Contraceptive Patch Now Entering Phase 3

Agile Therapeutics, Inc., presented new detailed data on ethinyl estradiol (EE) and levonorgestel (LNG) hormone levels, safety and ovulation suppression on its lead product, AG200-15, an innovative low-dose weekly contraceptive patch now entering Phase 3 clinical trials to show efficacy, safety and tolerability. Agile's proprietary SKINFUSIONTM technology makes it possible to use the trusted hormone combination of ethinyl estradiol and levonorgestrel in a weekly, low-dose patch that is comfortable to wear.


Presented at two poster sessions at the American College of Obstetricians and Gynecologists (ACOG) 57th Annual clinical Meeting, in Chicago, IL, Agile reported that the EE and LNG levels for AG200-15 were consistent over three cycles and within range of low-dose oral contraceptives. In the pharmacokinetic study, EE levels were significantly lower when compared to Levlen, a 30 mcg combination oral contraceptive. AG200-15 will be the first contraceptive patch to offer women a low-dose option consistent with market trends for oral contraceptives.


Data on ovarian suppression indicated that AG200-15's efficacy will be comparable to popular, currently marketed oral contraceptives. The bleeding profile and other hormone related adverse events were similar to published data for low-dose oral contraceptives. Patients reported excellent adhesion and skin tolerability.


According to market research conducted on behalf of Agile with 105 OB/GYN physicians who are significant prescribers of contraception, 89 percent said they would be likely to prescribe AG200-15. If it were available today, almost half said they would prescribe it immediately, showing that physicians recognize a large need with their patients for the comfort and convenience of Agile's low-dose, weekly contraceptive patch. This physician data supports earlier Agile market research with 1,500 women, of whom almost two-thirds who desired contraception said they would ask their doctor about AG200-15 if it were available to them.


Daniel R. Mishell, M.D., Professor in the Department of Obstetrics and Gynecology at the University of Southern California, and a member of Agile's Scientific Advisory Board, commented, "In these Phase 2 studies, AG200-15 demonstrated that it delivered a consistent EE level comparable to low-dose oral contraceptives. AG200-15's weekly, low-dose, efficacy and side effect profile will fill a major unmet need for a convenient, safe and efficacious contraceptive."


Marie Foegh, M.D., Chief Medical Officer and Vice President, Clinical Research and Development of Agile, said, "We are happy to share important additional data on our clinical program for Agile's weekly, low-dose contraceptive patch during this very important scientific meeting. Based on the ovulation suppression data, bleeding and hormone related adverse event profile, we selected AG200-15 as the lead contraceptive patch candidate for Phase 3 development."















Pharmacokinetic Study (Monday, Poster #28)


The pharmacokinetic study was an open-label, randomized, comparative, single-center, two-period cross-over study with 39 patients that evaluated two contraceptive patches to see if the systemic exposure of ethinyl estradiol (EE) and levonorgestrel (LNG) were comparable to the low-dose oral contraceptive, Levlen. As intended, both the EE and LNG exposure of both patches were less than Levlen and consistent with the levels targeted by the company.


Phase 2b Study (Tuesday, Poster #27)


In this multi-centered, multi-cycle Phase 2b safety and efficacy study of 123 women, the Company studied patches with different estrogen and progestin doses for three cycles to identify the regimen providing the best efficacy (as demonstrated by ovulation suppression), cycle control and tolerability at the lowest hormonal dose. Top-line results from the trial showed there was a clear dose-response to ovulation suppression and cycle control. AG200-15 provided the greatest ovulation suppression with the best cycle control of the three regimens studied.


About AG200-15, Agile's Low-Dose Contraceptive Patch


AG200-15 with SKINFUSIONTM technology is a low-dose, weekly contraceptive patch that is entering Phase 3 development with a clearly defined regulatory pathway. SKINFUSIONTM technology makes it possible to utilize the trusted hormone combination of levonorgestrel and ethinyl estradiol in a contraceptive patch. AG200-15 has completed Phase 2 development and met all target endpoints, including providing estrogen dose, ovulation suppression, and side-effect similar to low-dose oral contraceptives. The patch was designed for flexibility and comfort.


About Estrogen


Estrogen is associated with certain common side effects, such as breast tenderness, bloating/weight gain and nausea. These side effects are believed to be related to the level of estrogen exposure. In some rare cases, high estrogen levels are thought to be linked with serious, cardiovascular side effects in some women. Therefore, low doses of estrogen in hormonal contraception are desired.


Source
Agile Therapeutics, Inc.


View drug information on Estradiol Transdermal System.

четверг, 22 сентября 2011 г.

Research Lacking On Why Heart Disease Is More Deadly For Women

A woman who has heart disease
is 50% more likely to die from it than a man who has it. Although experts
can point to a number of possible explanations for this, the research on
women and heart disease remains inadequate, says the new edition of a
Harvard Medical School report, The Healthy Heart: Preventing, detecting,
and treating coronary artery disease.


Even though men are more likely to develop cardiovascular disease than
women, about 38% of women who have a heart attack die within a year of the
event, compared with 25% of men. And women are almost twice as likely as
men to have a second heart attack within six years of the first.



The science behind the differences is unclear. These are some of the
theories discussed in The Healthy Heart:


-- Age. Women seem to become more vulnerable to heart disease only
after their estrogen levels fall with menopause, and so they tend
to suffer first heart attacks later than men. Advanced age may
make it more difficult to survive a heart attack.


-- Coronary microvascular disease. This new diagnosis may apply to
50% to 60% of women, compared with 20% of men. These people have
chest pain when they are active or stressed, but on angiograms,
their coronary arteries appear clear. Studies show that women
with coronary microvascular disease have a higher risk for heart
attack or stroke.


-- Inferior diagnosis and treatment. Some studies suggest women's
heart problems don't receive the same attention as men's.


-- Incomplete understanding of symptoms. Classic heart attack
symptoms were defined based on studies on men. These symptoms
don't always occur in women, which may delay diagnosis and
treatment.


Harvard Health Publications

health.harvard.edu

четверг, 15 сентября 2011 г.

Symbollon Pharmaceuticals, Inc. Evaluates The Clinical Effects Of IoGen(TM) On Fibrocystic Breast Disease

Iodine has been used as an
antimicrobial for the last century. Much has been written about molecular
iodine yet many women suffering from Fibrocystic Breast Disease (FBD) are
unaware that studies being conducted may soon yield an effective
nonhormonal treatment.



While there are several breast cancer drugs on the market, all
available hormonal therapies have significant adverse events. In contrast,
IoGen is a nonhormonal treatment that allows for safe long-term use with
little or no side effects.



"Current research provides substantive support for the initiation of
human clinical studies on the use of molecular iodine as a treatment for
breast disease," stated Paul Desjourdy, President and CEO, Symbollon
Pharmaceuticals, Inc. "The possibility that IoGen may be used as a
treatment for breast cancer makes it all the more important that we
expedite the commercialization time line."



The Company believes IoGen has the ability to eliminate excess cell
growth in female reproductive tissue, including the breast, ovaries and
uterus. Other indications for IoGen include the treatment or prevention of
endometriosis, ovarian cysts, and premenopausal breast cancer.



Symbollon Pharmaceuticals, Inc. is now in FDA Phase III clinical trials
for the evaluation of IoGen (I2) for pain/tenderness associated with FBD
and with potential to treat female reproductive organ cancers.



The importance of (I2) in the treatments for mammary gland dysfunctions
has been corroborated in human and animal models.



Seaweeds, containing high quantities of iodine in several chemical
forms including (I2), have been associated with low incidences of benign
and malignant breast disease in Asian women.



Past studies by independent researchers have supported the possible
effectiveness of molecular iodine (I2) as a treatment for breast cancer.


-- Researchers at Drexel University College of Medicine found that
molecular iodine alters the gene expression profile in the human breast
cancer cells. Dr. Bernard Eskin remarked that these changes may be
responsible for molecular iodine's inhibition of breast cancer
promotion that has been repeatedly observed in animal models.


-- Some researchers investigating the connection between breast tissue and
iodine observed that frequent childbirth and a long lactation period
are known to reduce the risk of breast cancer.



Symbollon is now conducting its IoGen (I2) Phase III pivotal pain
study. Results are expected in first quarter of 2008. For more information
on IoGen(TM), please visit the company's web site at: symbollon or
mybreastpain.


Symbollon Pharmaceuticals, Inc.

symbollon

четверг, 8 сентября 2011 г.

New Treatments for Common Vaginal Infection, Bacterial Vaginosis, Being Studied

Whether a two-week regimen using a stainless steel douching device can eradicate the most common vaginal infection is
under study at the Medical College of Georgia.


MCG researchers want to know whether the device can eliminate bacterial vaginosis and the distinctive odor that typically
accompanies the infection, says Dr. Daron G. Ferris, family medicine physician, director of the Gynecologic Cancer Prevention
Center at MCG Medical Center and the study's principal investigator.


MCG is the only site in the nation for a two-week test of the device that is based on the same premise as stainless steel
bars chefs use to eliminate undesirable odors from their hands. Participants in a small pilot study who used the device for
one week indicated they were beginning to see improvement, says Dr. Eileen D. Dickman, clinical researcher, coordinator of
the Gynecologic Cancer Prevention Center and a co-investigator.


"Bacterial vaginosis is the most common type of vaginal condition that women experience and yet its etiology is poorly
understood," says Dr. Ferris. "Basically it's an alteration of the vagina's ecosystem. It gets that way because the
lactobacilli, the good bacteria in the vagina, are wiped out."


Good bacteria are critical to the vagina's natural, continuous cleansing process. They secrete lactic acid, which makes the
vagina very acidic, and hydrogen peroxide to kill bad bacteria. Dead cells are carried away in the normally clear discharge.
When the system is disrupted, a woman's natural defense against sexually transmitted diseases decreases, leaving her much
more vulnerable to infections such as HIV, Chlamydia and human papillomavirus. Multiplying bad bacteria produce an
undesirable odor and vaginal discharge may be thick and white.


All sexually active women are at risk for this imbalance; for some unknown reason black women have twice the risk. Regular
vaginal douching may also be a factor, says Dr. Ferris, noting that his counterparts around the world might disagree. "In
America we feel that douching is nonselective: it washes out the good and the bad bacteria," says Dr. Ferris. "After you
douche, if the good bacteria isn't re-established first, the bad bacteria take over and you have a potential problem."
Studies and experience have shown that a major reason women douche is because their mothers did, Dr. Ferris says.


While many European physicians encourage the habit, Dr. Ferris is among the many American physicians who advise their
patients against douching. He wonders if the cylindrical stainless steel device, developed collaboratively by researchers at
Abbott Research Group, Inc. and Carnegie Mellon University in Pittsburgh, may one day be a douching technique he'd recommend.
















Women can easily use the device in the shower. A compartment attached to the device via a tube is filled with body
temperature tap water and placed at an elevated level so the natural force of gravity gently washes out the vagina for a few
minutes.


"I didn't believe this until they sent me a stainless steel chef's bar to try," says Dr. Ferris. "If you get garlic or onion
on your fingers, you use this stainless steel bar to wash your hands without soap, and it gets rid of the odor. Since
bacterial vaginosis is associated with this odor, it's thought the stainless steel has some effect on the whole process and
it could potentially eliminate the infection and the odor as well. This could be a non-pharmacologic, alternative medicine
approach," says Dr. Ferris.


"The standard treatment today is antibiotics to kill the bad bacteria so hopefully the good bacteria can resume dominance.
The goal of the douching device is to clear the infection without antibiotics. We don't know if it will," says Dr. Ferris.
"But, it might be an option other than antibiotics which are not 100 percent effective and can lead to secondary infections,
including yeast."


MCG also is participating in a multi-site study of the first potential new antibiotic for bacterial vaginosis in at least 25
years, a drug called tinidazole, which already has Food and Drug Administration approval to treat trichomoniasis vaginitis,
another common vaginal infection.


Europeans have used tinidazole for years to treat bacterial vaginosis and experience has shown the drug causes less
gastrointestinal side effects than two antibiotics used routinely in the United States. Its efficacy rate may be equivalent
or better than the existing drugs, clindamycin phosphate and metronidazole, Dr. Ferris says.


"We have had the same two antibiotics for a long time so our treatment options are rather limited," says Dr. Ferris, who is
excited about the opportunity to find better treatments for this very common infection with a recurrence rate of about 80
percent.


Women age 18 and older with bacterial vaginosis are eligible for both studies. The douching study is sponsored by Abbott
Research Laboratories and the antibiotic study by Presutti Laboratories.


Contact: Toni Baker

tbakermcg.edu

706-721-4421

Medical College of Georgia

mcg.edu


View drug information on Clindamycin phosphate topical gel.

четверг, 1 сентября 2011 г.

Weak Bladders Deter Many Young Women From Sports Participation

A weak bladder is putting many young women off participating in sport, or prompting them to give it up altogether, suggests research published ahead of print in the British Journal of Sports Medicine.


The prevalence of urinary stress incontinence, defined as an involuntary leakage of urine, is relatively high among women, with some research putting the figure as high as 46%.



The researchers asked 679 Italian women about whether they had ever had urinary stress incontinence. All them were still having regular periods, and took part in non-competitive sports.


The anomymous responses showed that around 1 in 7 (15%) said they suffered from the condition. On average, the women had been putting up with the symptoms for six years.


Being overweight and having had children boosted the risk of urinary stress incontinence.



Of those affected, almost half said the condition occurred during routine activities, while one in three said it occurred solely during sporting activities. One in five said it occurred in both circumstances.


The most risky sports for women with the problem, in descending order of magnitude, were basketball, athletics, and tennis or squash.


Over half of those complaining of the problem experienced up to three episodes of involuntary leakage a month, but for around one in five the frequency of episodes exceeded more than three a week.


One in 10 women said that stress incontinence had prompted them to give up their favourite sport.


A further one in five said that the condition had restricted or forced them to change their activities, in a bid to avoid the risk of leakage.


The figures would have been considerably higher if women who had gone through the menopause had been included in the sample, say the authors.


They conclude that urinary stress incontinence impacts on the quality of women's lives, affecting many aspects of routine and recreational activities, but few women seek help for the condition, they say.


"They should be given information and offered diagnostic and conservative therapeutic options," including pelvic floor exercises, which can be very helpful, they add.


"The impact of urinary stress incontinence in young and middle aged women practising recreational sports activity: an epidemiological study."

Online First Br J Sports Med 10.1136/bjsm.2008.049072

bjsm.bmj

British Journal of Sports Medicine

четверг, 25 августа 2011 г.

Lipstick Contains Detectable Levels Of Lead Says Campaign Group Report

A report released yesterday by the Campaign for Safe Cosmetics (CSC), a coalition of women's, public health, and environmental groups campaigning for
the phasing out of toxins in cosmetics, has suggested that over half of 33 top brands of lipsticks on sale in the US contain detectable levels of
lead.


The report said that tests conducted by an independent laboratory during September this year found that 61 per cent of 33 brand-name red lipsticks contained
detectable levels of lead ranging from 0.03 to 0.65 parts per million (ppm). The lipsticks were bought in Boston, Hartford, Connecticut, San Francisco and
Minneapolis.


One third of the lipsticks tested by the laboratory were found to contain more than the 0.1 ppm limit imposed by the US Food and Drug Administration on candy
and sweets. Although the limit for candy was set to protect children from ingesting lead, the CSC is using this comparison to show that lipstick, which is
put directly onto the lips, is also a source of directly ingested lead, to which pregnant women for example are particularly vulnerable. But the CSC pointed
out that the FDA has not set a limit for lead in lipstick.


The CSC report said 39 per cent of the lipsticks tested had no detectable levels of lead, suggesting it was possible to make them without lead. However,
cost does not seem to be a factor, they said, since cheaper brands such as Revlon, selling at 7.49 dollars an item had no detectable levels of lead but the
most expensive lipstick they tested, the Dior Addict brand, selling at 24 dollars 50 an item had higher levels than some of the other lipsticks.


The CSC said that the top brands that tested positive for lead in their red lipsticks included:

L'Oreal Colour Riche "True Red" (lead level of 0.65 ppm),
L'Oreal Colour Riche "Classic Wine" (0.58 ppm),
Cover Girl Incredifull Lipcolor "Maximum Red" (0.56 ppm), and
Dior Addict "Positive Red" (0.21 ppm).

Referring to studies that said there is no safe level for lead, and that it is a toxin that builds up in the human body because we can't excrete it, Dr Mark
Mitchell, president of the Connecticut Coalition for Environmental Justice, said:


"Lead-containing lipstick applied several times a day, every day, can add up to significant exposure levels."


Stacy Malkan, author of the new book, "Not Just a Pretty Face: The Ugly Side of the Beauty Industry", also referred to the build up of toxins like lead in
the body, and said the cosmetics industry needs to "clean up its act" and take immediate steps to reformulate products that contain lead.


John Bailey, EVP for Science Cosmetic, Toiletry, and Fragrance Association, said yesterday in a statement responding to the CSC report that despite repeated
allegations to the contrary over the years, the cosmetics industry does not add lead to its products; the metal occurs naturally in a range of ingredients, as
it does "everywhere in the environment".















He said consumers were exposed to lead every day when they "eat, drink water, and breathe the air".


Bailey pointed out that the average quantity of lead a woman would be exposed to from using cosmetics amounted to 1,000th of the amount she would ingest from
eating food, breathing in air and drinking water that met the drinking water standards set by the Environmental Protection Agency (EPA).


Referring to the FDA, Bailey said the agency set daily safe levels of lead exposure for adults, children and women who were expecting. And, implying a
contradiction to the CSC report, he said the FDA also set limits for lead in the colours used in lipsticks, and also tests them to make sure the limits are
obeyed. In fact he also said that the "products identified in the Campaign for Safe Cosmetics (CSC) report meet these standards."


Bailey said that for decades the cosmetics industry has worked to "minimize all product contamination, including lead", and they employed some of the world's
leading scientists to do this.


The Houston Chronicle reported yesterday that the FDA had no plans to act in response to the CSC report and the agency has been aware of concerns about lead
in lipstick for some time.


A pediatrician and assistant professor at Baylor College of Medicine, Dr Sara Rizvi, who was contacted by the Chronicle said the report's findings were
"troubling". However, she said there was no cause for panic since the report was inconclusive and even showed different levels of lead in the same
brand.


But Rizvi also went on to say that although more research was needed to establish conclusive evidence one way or the other, the industry should reformulate
products to remove lead completely, since this was an avoidable risk.


In high doses lead has been linked to learning and behavioural problems in children, such as reduced IQ, poorer school performance and aggression, said the
CSC. The unborn and the very young are especially vulnerable because lead affects early brain development.


Click here for the CSC report on lead in lipstick.


Click here to learn more about lead exposure and toxicity from the US Centers for Disease Control and
Prevention (CDC).


: Catharine Paddock